After Shuttering Genomics Division, Tapestry Risks Being Delisted from Nasdaq

Mar 07, 2005

NEW YORK, March 7 (GenomeWeb News) - Tapestry Pharmaceuticals, formerly known as NaPro BioTherapeutics, is in danger of being delisted to the Nasdaq Small-Cap Market for failing to keep its share price above $1 for 30 consecutive trading days, according to a news report.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

The Fall of the Yellow-Banded Bumblebee

York University researchers find genomic evidence of inbreeding in the yellow-banded bumblebee, according to Reuters.

If It Is to Help

In its survey of US adults, the Pew Research Center finds that views on the genetic engineering of animals depend on why it's done.

Bunch at Once

The Scientist reports agricultural researchers are working on a gene-stacking tool.

This Week in Nature

In Nature this week: statistical method for overcoming case-control imbalance issues, and more.

Main menu